Jean-Marc Renard, MS, MBA, joins as Chief Business Officer Emmanuel Prestat, PhD, joins as Computational…
nboutaouiSeptember 10, 2019
Independent Data Safety Monitoring Board (DSMB) confirms continuation of Phase II HERACLES study in acute…
nboutaouiJune 24, 2019
- First patents to cover the fundamental processes for accessing the human gut microbiome as…
nboutaouiMay 21, 2019
“Caelus Health, EnteroBiotix, Ferring Pharmaceuticals, and MaaT Pharma, in coordination with the Pharmabiotic Research Institute…
nboutaouiMay 21, 2019
MaaT Pharma Announces Second Positive DSMB Safety Assessment of Phase II HERACLES Study in Acute…
nboutaouiApril 9, 2019
Independent Data Safety Monitoring Board (DSMB) recommends to continue HERACLES study without modification. Lyon, France,…
nboutaouiFebruary 5, 2019
Data show achievement of primary endpoint, demonstration of functional microbiota restoration, inflammation reduction and positive…
nboutaouiDecember 2, 2018
Lyon, France, November 2, 2018 – MaaT Pharma announced today that the company will present…
MaaT PharmaNovember 6, 2018
Microbiome restoration biological drug product to be tested for safety and overall survival impact in…
MaaT PharmaOctober 12, 2018
